arthur fratamico  vitae pharmaceuticals inc  zoominfocom insider trading  fratamico arthur  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  fratamico arthur select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing purchase  pm vitae pharmaceuticals inc vtae fratamico arthurchief business officer    direct view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing equity swap  pm nana vitae pharmaceuticals inc vtae fratamico arthurchief business officer   direct view disposition  pm na vitae pharmaceuticals inc vtae fratamico arthurchief business officer   direct view disposition  pm na vitae pharmaceuticals inc vtae fratamico arthurchief business officer   direct view disposition  pm na vitae pharmaceuticals inc vtae fratamico arthurchief business officer   direct view disposition  pm na vitae pharmaceuticals inc vtae fratamico arthurchief business officer   direct view disposition  pm na vitae pharmaceuticals inc vtae fratamico arthurchief business officer   direct view option award  pm nana vitae pharmaceuticals inc vtae fratamico arthurchief business officer   direct view option award  pm na vitae pharmaceuticals inc vtae fratamico arthurchief business officer   direct view option award  pm na vitae pharmaceuticals inc vtae fratamico arthurchief business officer   direct view option award  pm na vitae pharmaceuticals inc vtae fratamico arthurchief business officer   direct view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  arthur john fratamico  west chester pa  intelius sign in we found arthur john fratamico in west chester pa arthur john fratamico intelius found that arthur john fratamico is a male between  and  years old from west chester pa we have connected them to  addresses  phones and  relatives or associates also known as arthur m fratamico art fratamico get report now age arthur john fratamico is in his s arthur has lived in west chester pa philadelphia pa minneapolis mn arthurs relatives lisa fratamico j fratamico jr fratamico arthur john fratamico zodiac signlibra gendermale professional status chubbybrain get report now want to know more about arthur get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about arthur or use our people search engine to find others get background check on arthur john fratamico get a criminal check on arthur john fratamico get a public record report on arthur john fratamico get a people search report on arthur john fratamico arthur john fratamicos contact information known cities lived in find out where arthur john fratamico has lived as well as arthur john fratamicos phone numbers and email addresses arthur john fratamico has lived in  states pennsylvania address for arthur john fratamico  a l west chester pa has lived in west chester pa philadelphia pa get full address report phone numbers associated with arthur john fratamico    west chester pa    ocean city nj    ocean city nj get full phone report email addresses associated with arthur john fratamico aonet aocom get email report arthur john fratamicos professional information information regarding arthur john fratamicos professional history find out previous places arthur john fratamico has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act arthur john fratamico has worked at  place company chubbybrain arthur john fratamicos experience title company chubbybrain job details chubbybrain is an offering by cb information services cbis that aims to capture and structure information about the innovation economy a world that includes highgrowth private companies venture capital firms private equity firms angel investors incubators and universities our goal is to cater this information to meet the growing needs of entrepreneurs investors corporations service providers and governments additional professional information on arthur john fratamico see arthur john fratamicos linkedin profile arthur john fratamicos social network and potential email matches find out potential social network profiles and potential email usernamed for arthur john fratamico arthur john fratamicos known social networks and potential email matches find all of arthur john fratamicos social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches arthur fratamico username matches arthurfratamico fratamicoarthur arthurfratamico fratamicoarthur arthurfratamico fratamicoarthur arthurfratamico fratamicoarthur afratamico popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches a fratamico intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here flexion therapeutics names arthur fratamico chief business officer flexion therapeutics names arthur fratamico chief business officer jun    et from flexion therapeutics inc woburn mass june   prnewswire  flexion therapeutics inc today announced that arthur j fratamico rph has joined the company as its first chief business officer he has more than  years of business development experience with emerging biopharmaceutical companies prior to joining flexion mr fratamico  led the business development efforts for trevena gemin x pharmaceuticals and mgi pharma while at mgi pharma mr fratamico led the corporate development group which oversaw numerous licensing transactions and acquisitions including that of aesgen akarx guilford and zycos ultimately culminating in the sale of mgi pharma to eisai while at gemin x mr fratamico closed the sale of that company to cephalon for  million we are delighted to have someone of arts experience and capability join our executive team particularly at this exciting time for the company said michael clayman md chief executive officer of flexion our recently announced positive phase  data for fx has accelerated interest from potential partners and art will play a key role advancing these discussions fratamico holds a bachelors degree in pharmacy from philadelphia college of pharmacy and science and a masters in business administration with a dual concentration in marketing and finance from drexel university about flexion therapeutics flexion discovers and develops innovative therapeutics for musculoskeletal disorders in our efforts to provide products with superior efficacy and safety we are merging novel pharmacology with local sustained delivery of drug to the site of disease  an approach that aims to ensure lasting therapeutic effect and systemic safety we are currently advancing a portfolio of bestinclass drug candidates that have the potential to treat mild moderate and severe forms of osteoarthritis topline data for fx an intraarticular sustained release p map kinase inhibitor and our lead compound showed prolonged improvement in joint pain and function throughout the week duration of the phase  study fx an intraarticular sustained release steroid will begin phase  clinical study imminently fx an intraarticular sustained release trka inhibitor is being developed to safely address the intractable pain associated with end stage osteoarthritis for more information please visit wwwflexiontherapeuticscom media contacts corporate contact tony russo phd lisa davidson mba matt middleman md vice president finance and administration russo partners t  t  ldavidsonflexiontherapeuticscom t  tonyrussorussopartnersllccom mattmiddlemanrussopartnersllccom source flexion therapeutics inc related links httpwwwflexiontherapeuticscom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more dec    et preview flexion therapeutics secures  million in series b financing may    et preview flexions lead osteoarthritis drug candidate demonstrates significant prolonged improvement in pain and function in phase  trial my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search trevena inc menu menu home about trevena about trevena management board of directors careers pipeline our pipeline oliceridine trv moderatetosevere acute pain how oliceridine works oliceridine development trv trv development trv trv platform what is a biased ligand trevenas able platform history of biased ligands investors investor relations press releases investor presentations analyst coverage corporate governance management board of directors committee composition contact the board financials  filings sec filings annual reports and proxies quarterly results stock information historic stock lookup investment calculator investor faqs publications all publications oliceridine publications trv publications biased ligand publications contact contact directions to trevena investor relations press releases investor presentations analyst coverage corporate governance financials  filings stock information investor faqs   corporate presentation investor inquiriesjonathan violin phd vp corporate strategy  ir  x jviolintrevenacom prmedia inquiriesprtrevenacom trevena names arthur fratamico chief business officer proven industry executive brings experience in corporate and business development king of prussia pa april th  – trevena inc the leader in gprotein coupled receptor gpcr biased ligand drug discovery today announced the appointment of arthur fratamico rph mba to the position of chief business officer in this role mr fratamico is responsible for trevenas business and strategic development we are delighted to welcome art to the team said maxine gowen phd president and chief executive officer of trevena art’s rich sellside experience will be invaluable to the strategic development of trevena as we move through phase  clinical trials with trv for acute heart failure and continue to advance our discovery portfolio of nextgeneration gpcr drugs mr fratamico brings to trevena nearly  years of experience in the pharmaceutical and biotechnology industries prior to joining trevena he served as chief business officer at geminx pharmaceuticals where he was responsible for overseeing corporate development activities which culminated recently in the sale of the company to cephalon for mm before geminx mr fratamico spent nine years at mgi pharma inc in several key leadership roles including vice president business development and licensing he previously worked for  years at hoechst marion roussel in various assignments including sales product marketing and commercial development mr fratamico is also a registered pharmacist and earned an mba with a dual concentration in marketing and finance from drexel university i am excited to be joining such a high caliber team working at the forefront of biased gpcr ligands said mr fratamico trevena’s emerging portfolio of gpcr programs provides fantastic potential for corporate development and collaboration going forwards this is a great opportunity about biased ligands and trv one third of modern medicinal products target gpcrs and they remain the largest class of targets currently under clinical evaluation however traditional ligands either turn on or turn off all of the signaling pathways engaged by a particular receptor which can result in efficacy limitations or undesirable adverse effects in contrast trevenas novel drug discovery approach is focused on designing gpcr ligands that are biased toward activating one key receptor signaling pathway while blocking another these biased ligands provide an enhanced level of drug specificity which allows enhanced efficacy or decreased side effects to be designed into the drug candidate trv is trevenas most advanced program and a firstinclass agent that due to its unique spectrum of biological effects could provide a major advance in the treatment of acute heart failure it targets atr which plays a central role in the pathophysiology of heart failure based on its profile in animals trv is expected to rapidly provide symptomatic benefit while promoting an improvement in target organ function in patients with acute heart failure about trevena trevena inc is a leader in the discovery and development of gpcr biased ligand drugs trevena combines a powerful and efficient drug discovery platform with extensive development experience to yield a rich linked portfolio of novel medicines trevenas proprietary advanced biased ligand explorer or able™ platform includes customized assays proprietary software animal models and unique biological signaling information across multiple gpcrs that allow for the discovery optimization and development of unique biased ligands into differentiated new medicines the companys drug discovery technology is based on extensive research from the laboratories of leading scientists in the gpcr field  robert j lefkowitz md and howard a rockman md of duke university medical center trevenas pipeline is currently focused on programs for cardiovascular and cns indications with significant unmet medical needs founded in  trevena is based in king of prussia pennsylvania and is a privately held company backed by leading investors including alta partners healthcare ventures nea polaris and yasuda enterprise development company about trevena management board of directors careers pipelineolinvo™oliceridine injectiontrvtrv platformable™ platformhistory of biased ligands investors press releases investor presentations analyst coverage corporate governance financials  filings stock information investor faqs publicationsolinvo™trvbiased ligand contactdirections follow us copyright  trevena inc arthur fratamico vitae pharmaceuticals vp  bus development profile subscribecontact us homeoverviewfree trialsubscribeservicesuse casesapi feedsreportsfaq tech executive download record   vcard  csv  pdf name   arthur fratamico title   vp  bus development company name   vitae pharmaceuticals company status   private  independent industry   biopharmaceutical profile   social media   company news   facebook   youtube   funding history   company transaction list mailing address    west office center drive  fort washington pa  usa  map phone     website   wwwvitaepharmacom company description   vitae pharmaceuticals nadaq vtae is developing a robust and growing portfolio of novel product candidates generated by contour our proprietary computationallybased sbdd platform investors   atlas ventureintel capitalnew enterprise associatesprospect venture partnersthe wellcome trustundisclosedvenrock free trial want unlimited access to the complete database with thousands of technology companies vcs and transactions for only  per month start your free  day trial now – no obligation or credit card required about venturedeal founded in  venturedeal is a database that provides the latest information about venture capital firms venturebacked technology companies and transactions throughout north america learn more » home overview service firms tech entrepreneurs venture investors services subscribe use cases faq terms of use privacy policy contact login  venturedeal inc menlo park ca all rights reserved trevena names arthur fratamico chief business officer  business wire trevena names arthur fratamico chief business officer proven industry executive brings experience in corporate and business development april    am eastern daylight time king of prussia pabusiness wiretrevena inc the leader in gprotein coupled receptor gpcr biased ligand drug discovery today announced the appointment of arthur fratamico rph mba to the position of chief business officer in this role mr fratamico is responsible for trevena’s business and strategic development “we are delighted to welcome art to the team” said maxine gowen phd president and chief executive officer of trevena “art’s rich sellside experience will be invaluable to the strategic development of trevena as we move through phase  clinical trials with trv for acute heart failure and continue to advance our discovery portfolio of nextgeneration gpcr drugs” mr fratamico brings to trevena nearly  years of experience in the pharmaceutical and biotechnology industries prior to joining trevena he served as chief business officer at geminx pharmaceuticals where he was responsible for overseeing corporate development activities which culminated recently in the sale of the company to cephalon for mm before geminx mr fratamico spent nine years at mgi pharma inc in several key leadership roles including vice president business development and licensing he previously worked for  years at hoechst marion roussel in various assignments including sales product marketing and commercial development mr fratamico is also a registered pharmacist and earned an mba with a dual concentration in marketing and finance from drexel university “i am excited to be joining such a high caliber team working at the forefront of biased gpcr ligands” said mr fratamico “trevena’s emerging portfolio of gpcr programs provides fantastic potential for corporate development and collaboration going forwards this is a great opportunity” about biased ligands and trv one third of modern medicinal products target gpcrs and they remain the largest class of targets currently under clinical evaluation however traditional ligands either turn on or turn off all of the signaling pathways engaged by a particular receptor which can result in efficacy limitations or undesirable adverse effects in contrast trevena’s novel drug discovery approach is focused on designing gpcr ligands that are “biased” toward activating one key receptor signaling pathway while blocking another these biased ligands provide an enhanced level of drug specificity which allows enhanced efficacy or decreased side effects to be designed into the drug candidate trv is trevena’s most advanced program and a firstinclass agent that due to its unique spectrum of biological effects could provide a major advance in the treatment of acute heart failure it targets atr which plays a central role in the pathophysiology of heart failure based on its profile in animals trv is expected to rapidly provide symptomatic benefit while promoting an improvement in target organ function in patients with acute heart failure about trevena trevena inc is a leader in the discovery and development of gpcr biased ligand drugs trevena combines a powerful and efficient drug discovery platform with extensive development experience to yield a rich linked portfolio of novel medicines trevenas proprietary advanced biased ligand explorer or able™ platform includes customized assays proprietary software animal models and unique biological signaling information across multiple gpcrs that allow for the discovery optimization and development of unique biased ligands into differentiated new medicines the companys drug discovery technology is based on extensive research from the laboratories of leading scientists in the gpcr field  robert j lefkowitz md and howard a rockman md of duke university medical center trevenas pipeline is currently focused on programs for cardiovascular and cns indications with significant unmet medical needs founded in  trevena is based in king of prussia pennsylvania and is a privately held company backed by leading investors including alta partners healthcare ventures nea polaris and yasuda enterprise development company for more information about the company please visit wwwtrevenainccom contacts trevena incalastair southwell asouthwelltrevenainccom contacts trevena incalastair southwell asouthwelltrevenainccom search advanced news search advanced news search log in sign up arthur fratamico  former chief business officer at vitae pharmaceuticals inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink arthur fratamico former chief business officer at vitae pharmaceuticals inc overview in the news relationships paths education career history investments transactions arthur fratamico former chief business officer at vitae pharmaceuticals inc overview age  born  number of relationships this person is connected to  people in the news see more philadelphia inquirer july   people in the news fiercebiotech july   vertexs mueller steps down from rd position relationships see details richard gregg chief scientific officer at vitae pharmaceuticals inc jeffrey s hatfield advisor at atlas venture inc richard steven morris former chief financial officer at vitae pharmaceuticals inc steven dykstra former senior directormanufacturing operations at mgi pharma inc robert d bailey president at naurex inc scott applebaum general counsel  corporate secretary at vitae pharmaceuticals inc carole a sable chief medical officer at vitae pharmaceuticals inc leon o moulder jr cofounder at tesaro inc david a claremon vice presidentchemistry at vitae pharmaceuticals inc gerard m mcgeehan vice presidentdiscovery biology at vitae pharmaceuticals inc see  more listings with relsci professional start my free trial ➤ see  more paths to arthur fratamico arthur fratamico you connections via relationship science arthur fratamico sync your contacts to see how you can connect with arthur fratamico start my free trial ➤ see more educational background   drexel university drexel is a comprehensive global research university ranked among the top  in the nation with approximately  students drexel is one of america’s  largest private universities drexel has built its global reputation on core achievements that include leadership in experiential learning through drexel coop a history of academic technology firsts recognition as a model of best practices in translational useinspired research founded in  in philadelphia drexel now engages with students and communities around the world via three philadelphia campuses and other regional sites drexel university sacramento the academy of natural sciences of drexel university the nation’s oldest major natural science museum and research organization international research partnerships including china and israel drexel online one of the oldest and most successful providers of online degree programs drexel is one of philadelphia’s top  employers and a major engine for economic development in the region drexel has committed to being the nation’s most civically engaged university with community partnerships integrated into every aspect of service and academics drexel’s ongoing strategic plan “transforming the modern urban university” guides the university’s stcentury trajectory   university of the sciences  philadelphia college of pharmacy career history chief business officer    vitae pharmaceuticals inc vitae pharmaceuticals inc is a clinicalstage biopharmaceutical company its focus is on discovering and developing novel small molecule drugs for diseases including chronic kidney disease diabetes and alzheimers disease and autoimmune disorders acute coronary syndrome and immunooncology the company was founded by john j baldwin bartosz a grzybowski george m whitesides and eugene shakhnovich on may   and is headquartered in fort washington pa chief business officer   prior flexion therapeutics inc flexion therapeutics inc is a pharmaceutical company which focuses on the development and commercialization of novel local therapies the firm specializes in treatment of patients with musculoskeletal conditions including osteoarthritis it offers products under the zilretta brand the company was founded by michael d clayman and neil bodick on november   and is headquartered in burlington ma chief business officer   prior trevena inc trevena inc is a clinical stage biopharmaceutical company it discovers develops and intends to commercialize therapeutics that use a novel approach to target g protein coupled receptors the company product pipeline consists of trv trv trv and delta opiod trevena was founded by robert joseph lefkowitz scott dewire howard a rockman jonathan violin and erin whalen on november   and is headquartered in king of prussia pa chief business officer prior gemin x pharmaceuticals us inc gemin x pharmaceuticals us inc is engaged in the development of cancer therapeutics it offers mimetic and telomere capping programs as well as screening medicinal chemistry and preclinical development services the company was founded by gordon c shore in  and is headquartered in malvern pa vice presidentbusiness development  licensing prior mgi pharma inc mgi pharma inc develops manufactures  markets pharmaceutical and medical products for therapeutic markets the companys products include aloxi injection dacogen gliadel water hexalen capsules and salagen tablets it has alliances with helsinn healthcare sa kissei pharmaceutical co ltd dainippon pharmaceutical co ltd pfizer inc and novartis pharma ag the company was founded in  and is headquartered in bloomington mn professional prior hoechst marion roussel inc hoechst marion roussel discovers develops manufactures and sells proprietary and generic pharmaceutical products investments details hidden flexion therapeutics inc flexion therapeutics inc is a pharmaceutical company which focuses on the development and commercialization of novel local therapies the firm specializes in treatment of patients with musculoskeletal conditions including osteoarthritis it offers products under the zilretta brand the company was founded by michael d clayman and neil bodick on november   and is headquartered in burlington ma transactions details hidden flexion therapeutics inc raised money in a private placement transaction other affiliations arthur fratamico is affiliated with vitae pharmaceuticals inc flexion therapeutics inc trevena inc gemin x pharmaceuticals us inc mgi pharma inc hoechst marion roussel inc youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ vitae pharmaceuticals adds to leadership team with appointment of arthur fratamico as chief business officer richard morris as chief financial officer nasdaqvtae english français register sign in vitae pharmaceuticals adds to leadership team with appointment of arthur fratamico as chief business officer richard morris as chief financial officer july    et  source vitae pharmaceuticals inc fort washington pa july   globe newswire  vitae pharmaceuticals inc a clinicalstage biotechnology company focused on discovering and developing small molecule drugs today announced that art fratamico mba has been named chief business officer and richard morris cpa has joined the company as chief financial officer mr fratamico oversees vitaes corporate and business development plans mr morris has assumed responsibility for the companys finance investor relations and administration departments we are delighted to welcome art and rich to the vitae team we believe that arts experience successfully leading corporate development and commercial efforts at large and small pharmaceutical firms and richs track record of finance management and strong executive leadership will prove vital to vitae as we advance our pipeline of novel therapies said jeffrey hatfield vitaes president and chief executive officer mr fratamico joins vitae with more than  years of experience in the pharmaceutical industry most recently he served as chief business officer of flexion therapeutics where he led all corporate development activities for the companys research and development programs prior to that mr fratamico served as the chief business officer of trevena inc where he led the companys public and investor relations programs and oversaw the commercial planning marketing and forecasting activities for their product portfolio he has also held senior positions in business and corporate development at gemin x pharmaceuticals mgi pharma and hoechst marion roussel mr fratamico holds an mba in marketing from drexel university and a bs in pharmacy from philadelphia college of pharmacy and science vitaes ability to leverage its drugdiscovery platform has resulted in the rapid discovery of small molecule product candidates in important therapeutic areas including diabetes alzheimers autoimmune disorders acute coronary syndrome and atopic dermatitis said mr fratamico i look forward to playing a key role in the expansion of vitaes business operations mr morris has more than  years of experience in the life sciences industry most recently he served as vice president financial planning and strategic analysis for viropharma where he was responsible for the companys global short and longterm financial planning companywide strategic planning business growth and profit optimization ma valuations and corporate finance defense initiatives prior to that he served as viropharmas controller and chief accounting officer where he directed the companys consolidated financial accounting tax and finance operations mr morris holds a bs in accounting from saint josephs university in philadelphia and is a certified cpa vitaes proprietary discovery platform has positioned the company as a leader in structurebased drug discovery and enabled the company to expand its clinical development efforts said mr morris i am thrilled to join vitae as it works to optimize its discovery and development platform to progress compounds in important disease areas about vitae pharmaceuticals vitae pharmaceuticals is a clinicalstage privately held biopharmaceutical company discovering and developing novel smallmolecule drugs for diseases where there are significant unmet medical needs the company is developing a robust and growing portfolio of potential first or bestinclass product candidates generated by its proprietary contour® structurebased discovery platform including vtp for diabetes and metabolic syndrome vtp for alzheimers disease vtp for autoimmune disorders vtp for acute coronary syndrome and vtp for atopic dermatitis vitae strives to be the best in the world at structurebased drug discovery combining contour® with the insights of a team of accomplished scientists to rapidly discover and advance product candidates for validated but difficulttodrug targets in multiple disease areas   for additional information please visit the companys website at wwwvitaepharmacom media contact tony plohoros  tplohorosdegreesprcom related articles other press releases by vitae pharmaceuticals inc vitae pharmaceuticals to present at wells fargo healthcare conference september    vitae pharmaceuticals to present at wedbush pacgrow healthcare conference august    vitae pharmaceuticals appoints scott applebaum as general counsel and corporate secretary august    vitae pharmaceuticals reports second quarter  operating and financial results august    vitae pharmaceuticals to announce second quarter  financial results on august   august     other news releases in directors and officers in the last  days profile vitae pharmaceuticals inc   subscribe via rss  subscribe via atom  javascript fort washington pennsylvania united states contact data media contact tony plohoros  tplohorosdegreesprcom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files vitae pharmaceuticals inc logo logo url  copy the link below formats available original medium small tags biotechnology pharmaceuticals management changes newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved